Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- ...
GSK’s depemokimab shows strong potential for United States Food and Drug Administration approval in asthma and chronic ...
In this edition of The People’s Pharmacy, Joe and Teresa Graedon also hear from a reader who lost their sense of smell after using zinc to treat a cold.
Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...
The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 ...
The FDA approved Amgen's and AstraZeneca's drug to treat chronic rhinosinusitis with nasal polyps, an inflammatory condition of the sinuses and nasal passages. The companies said the approval was ...
The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...
The FDA on Friday approved a new biologic as add-on maintenance treatment for inadequately controlled chronic rhinosinusitis ...
Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with nasal polyps (CRSwNP), a second biologic therapy has broken through with a | ...
AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately ...
Our noses are home to a variety of bacteria. Some, like Staphylococcus aureus or Streptococcus pneumoniae, can cause serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback